Viking Therapeutics, Inc. (0VQA.L)
USD 39.07
(-17.95%)
USD 39.07
(-17.95%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -73.37 Million | -48.39 Million | -47.58 Million | -21.77 Million | -24.75 Million | -18.75 Million |
| Net Income | -85.89 Million | -68.86 Million | -54.99 Million | -39.49 Million | -25.77 Million | -22.06 Million |
| Depreciation & Amortization | 292 Thousand | 291 Thousand | 296 Thousand | 277 Thousand | 260 Thousand | 477 Thousand |
| Deferred income taxes | -8.2 Million | - | 3.9 Million | 3.76 Million | 473 Thousand | -392 Thousand |
| Stock-based compensation | 16.75 Million | 8.67 Million | 6.1 Million | 5.81 Million | 3.74 Million | 2.6 Million |
| Change in working capital | 3.54 Million | 10.18 Million | -2.92 Million | 7.71 Million | -3.78 Million | 823 Thousand |
| Other non-cash items | 131 Thousand | 1.31 Million | 29 Thousand | 138 Thousand | 334 Thousand | -208 Thousand |
| Investing Cash Flow | -179.08 Million | 54.75 Million | 37.96 Million | 41.56 Million | 7.46 Million | -265.72 Million |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -478.3 Million | -121.43 Million | -168.01 Million | -280.63 Million | -362.4 Million | -348.2 Million |
| Sales/Maturities of investments | 299.21 Million | 176.18 Million | 205.97 Million | 322.2 Million | 369.86 Million | 82.47 Million |
| Other Investing Activities | -179.08 Million | 54.75 Thousand | 37.96 Thousand | 41.56 Thousand | 7463.00 | -265.72 Thousand |
| Financing Cash Flow | 271.37 Million | 4.16 Million | 6.88 Million | 950 Thousand | 887 Thousand | 300.27 Million |
| Debt repayment | - | - | - | - | - | -3.83 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -7121.00 | -6.79 Million | -707.00 | -296.00 | -151.00 | -127.00 |
| Common Stock Issuance | 276.52 Million | 826 Thousand | 7.58 Million | 1.24 Million | 1.03 Million | 296.6 Million |
| Other Financing Activities | 278.49 Million | 10.13 Million | -706.29 Thousand | -295.7 Thousand | -150.84 Thousand | 7.5 Million |
| Accounts receivables | 321 Thousand | - | - | - | - | - |
| Accounts payables | -1.01 Million | 7.08 Million | -2.54 Million | 1.55 Million | 1.47 Million | -508 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 4.24 Million | 3.1 Million | -383 Thousand | 6.16 Million | -5.25 Million | 1.33 Million |
| Cash at beginning of period | 36.63 Million | 26.37 Million | 29.11 Million | 8.37 Million | 24.77 Million | 8.98 Million |
| Cash at end of period | 55.51 Million | 36.63 Million | 26.37 Million | 29.11 Million | 8.37 Million | 24.77 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | -30 Thousand | -258 Thousand | - | - | - | - |
| Net cash flow / Change in cash | 18.88 Million | 10.26 Million | -2.74 Million | 20.74 Million | -16.4 Million | 15.79 Million |
| Free Cash Flow | -73.37 Million | -48.39 Million | -47.58 Million | -21.77 Million | -24.75 Million | -18.75 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -24.94 Million | -22.25 Million | -27.35 Million | -85.89 Million | -24.6 Million | -22.53 Million |
| Depreciation & Amortization | 87 Thousand | 75 Thousand | 74 Thousand | 292 Thousand | 74 Thousand | 73 Thousand |
| Deferred income taxes | - | - | - | -8.2 Million | -2.7 Million | -3.14 Million |
| Stock-based compensation | 8.98 Million | 7.08 Million | 7.98 Million | 16.75 Million | 4.08 Million | 4.48 Million |
| Change in working capital | -1.03 Million | -8.01 Million | 15.95 Million | 3.54 Million | 5.47 Million | 1.45 Million |
| Other non-cash items | -5.05 Million | -4.03 Million | 37 Thousand | 131 Thousand | 36 Thousand | 12 Thousand |
| Investing Cash Flow | 25.9 Million | -126.05 Million | -459.79 Million | -179.08 Million | 35.73 Million | -12.53 Million |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -149.98 Million | -229.82 Million | -596.6 Million | -478.3 Million | -97.53 Million | -79.39 Million |
| Sales/Maturities of investments | 175.88 Million | 103.76 Million | 136.8 Million | 299.21 Million | 133.26 Million | 66.86 Million |
| Other Investing Activities | 414.61 Million | -126.05 Million | 136.15 Million | -179.08 Thousand | 35.73 Thousand | -12.53 Thousand |
| Financing Cash Flow | 2.52 Million | 2.9 Million | 606.03 Million | 271.37 Million | 188 Thousand | -74 Thousand |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | 42.1 Thousand | - | -42.1 Thousand | -7121.00 | 1.67 Million | -74.00 |
| Common Stock Issuance | 46.65 Million | 2.9 Million | 597.11 Million | 276.52 Million | 269.94 Million | -269.83 Million |
| Other Financing Activities | -44.13 Million | 2.9 Million | 4.55 Million | -5.15 Million | -269.76 Million | 269.76 Million |
| Accounts receivables | 1.34 Million | -157 Thousand | - | - | - | - |
| Accounts payables | -10.83 Million | 5.86 Million | -2.28 Million | -1.01 Million | 1.8 Million | 100 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 8.45 Million | -13.87 Million | 18.23 Million | 1.01 Million | 3.67 Million | 1.35 Million |
| Cash at beginning of period | 43.91 Million | 195.57 Million | 55.51 Million | 36.63 Million | 37.18 Million | 69.51 Million |
| Cash at end of period | 50.34 Million | 43.91 Million | 195.57 Million | 55.51 Million | 55.51 Million | 37.18 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | -29 Thousand | 3000.00 | -48 Thousand | -30 Thousand | 50 Thousand | -68 Thousand |
| Net cash flow / Change in cash | 6.43 Million | -151.66 Million | 140.06 Million | 18.88 Million | 18.33 Million | -32.33 Million |
| Free Cash Flow | -21.96 Million | -28.51 Million | -6.13 Million | -73.37 Million | -17.64 Million | -19.65 Million |
SWEC-B
ZYDUSWELL
0HR2
HSTC
ASTRAL
AHCHY